Samuel Deleon, MD
Pulmonary Disease · Bronx, NYNPI 1770589111
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $892 of the $1,487 with a category attached, or 60.0%. F. Hoffmann-la Roche AG accounts for 60.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $952 and has fallen 66.1% since, to $323 in 2024.
Across 19 payments — averaging $78.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$892
- Abbott$146
- Genentech USA, Inc.$108
- Dexcom, Inc.$92
- Novo Nordisk$68
- Viiv Healthcare Company$59
- plus $121 from 3 others
Across 112 payments — averaging $13,989 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$965K
- Astrazeneca AB$162K
- Astrazeneca UK Limited$131K
- GSK$130K
- Novartis$122K
- Sanofi$35K
- plus $21K from 3 others
What the payments were for
- Speaking & faculty fees$89260%
- Food & beverage$59440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 1 | $892 |
| Abbott | 1 | $146 |
| Genentech USA, Inc. | 6 | $108 |
| Dexcom, Inc. | 1 | $92 |
| Novo Nordisk | 3 | $68 |
| Viiv Healthcare Company | 1 | $59 |
| GSK | 2 | $51 |
| AstraZeneca | 2 | $37 |
| AbbVie | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XOLAIR$892
- FREESTYLE LIBRE 3$146
How this compares
$1,487 in reported general payments places this provider in the 55th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $21,740 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $19,188 |
| JardianceEmpagliflozin | 12 | $12,102 |
| Incruse ElliptaUmeclidinium Bromide | 30 | $11,151 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $6,041 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 173 | $5,657 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $5,577 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,239 |
| Doxepin Hcl | 30 | $3,200 |
| Diclofenac Sodium ErDiclofenac Sodium | 34 | $2,512 |
| Fluocinonide | 21 | $1,972 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,124 |
| Ventolin HfaAlbuterol Sulfate | 16 | $844 |
| Montelukast Sodium | 78 | $522 |
| Omeprazole | 26 | $497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta | $51 | $30,33959 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $37 | $27,31758 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Bronx
- Raji AyinlaBronx$673K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.